Formycon Clears Major Legal Hurdle for Key Biosimilar

Formycon resolves patent dispute with Regeneron/Bayer for FYB203 biosimilar, but shares hit a new 52-week low amid financial reporting delays and forecasted losses.

Formycon has resolved a significant legal challenge, paving the way for the European launch of its promising biosimilar candidate, FYB203. The company reached a settlement with industry giants Regeneron and Bayer, removing a major uncertainty that had clouded the prospects of its development pipeline. This legal clarity arrives as the company's shares face substantial downward pressure in the capital markets.

Stock Price Hits New Low Amid Broader Concerns

Despite this operational milestone, investor sentiment remains weak. The stock declined 6.00 percent last Friday, closing at a new 52-week low of €17.22. Since the start of the year, the share price has fallen approximately 34.5 percent. Market observers attribute the pressure not only to general market conditions but also to a delayed financial reporting schedule. The company recently announced it will not publish its audited annual financial statements for 2025 until April.

Settlement Secures Path for Eye Disease Treatment

The settled dispute provides crucial commercial certainty for Aflibercept, a drug used to treat serious eye conditions including macular degeneration. The agreement allows Formycon to proceed with the commercialization of FYB203 across Europe and other territories without the threat of protracted patent litigation. This eliminates a key overhang that had previously weighed on the valuation of the company's product portfolio.

Analysts Maintain Stance Despite Forecasted Losses

Analysts at mwb research continue to uphold their buy recommendation for Formycon. However, they have recently highlighted commercialization challenges for other pipeline assets, such as FYB202. For the 2025 fiscal year, the market currently anticipates a substantial net loss of around €3.54 per share.

Management Faces Scrutiny on Strategy and Timeline

The company's management is now under pressure to provide detailed clarifications regarding its strategic direction and the precise launch timelines for its upcoming products. Formycon is scheduled to release its complete annual report alongside first-quarter figures on April 23, 2026. These disclosures are expected to be pivotal for the stock's future trajectory.